Rifampicin pharmacokinetics in children under the Revised National Tuberculosis Control Programme | |||
---|---|---|---|
분류 | pharmacokinetics | 조회 | 1390 |
발행년도 | 2015 | 등록일 | 2015-07-31 |
출처 | Int J Tuberc Lung Dis (바로가기) | ||
OBJECTIVE:
To evaluate serum levels of rifampicin (RMP) in children with tuberculosis (TB) at doses administered according to India's Revised National Tuberculosis Control Programme (RNTCP) 2009 report.
METHOD:
Prospective, open label, non-randomised single-dose study in 20 children aged 5-12 years.
SETTING:
The out-patient chest clinic of a tertiary care hospital, New Delhi, India.
RESULTS:
The median RMP dose administered was 9.56 mg/kg (range 9-12.64). Peak RMP concentration (Cmax) attained was 6.24 μg/ml (range 5.44-7.61) at time to Cmax of 3.5 h (range 3-4). RMP levels were significantly lower at 2, 3 and 4 h in children administered <10 mg/kg than those who received ⩾10 mg/kg (P < 0.05). A positive correlation between the RMP dose administered and Cmax was observed (r(2) = 0.748). RMP Cmax was <8 μg/ml in all patients, a level considered too low for therapeutic efficacy.
CONCLUSIONS:
Low serum concentrations of RMP were attained in children under the RNTCP 2009 weight band system. Peak RMP levels appear to be lower and the single dose elimination half-life shorter in children than in adults. To optimise treatment outcomes, revisions in RMP dose in children should take into consideration age-related differences in pharmacokinetics.
|
|
이전글 | Clinical Pharmacokinetics and Pharmacodynamics of the Endothelin Receptor Antagonist Macitentan. |
---|---|
다음글 | 포스포트랜스아세틸라제 억제 활성을 가지는 화합물을 포함하는 세균 감염 질환 예방 또는 치료용 약제학적 조성물 |